About
Prolocor develops a diagnostic test that quantifies FcγRIIa receptors on platelets to improve risk assessment and guide personalized treatment decisions in patients with cardiovascular disease and cancer.
Explore Prolocor's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.